A Phase 2 interventional study of Tislelizumab and Fruquintinib in Advanced Solid Tumors, sponsored by BeiGene. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-25.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was an open label, multicenter, Phase 2 study designed to assess the efficacy and safety of tislelizumab in combination with fruquintinib in participants with advanced or metastatic, unresectable gastric cancer (GC), or colorectal cancer (CRC) or non-small cell lung cancer (NSCLC). The study was conducted in 2 parts. Part 1 was the safety run-in stage to determine dose-limiting toxicity (DLT) and recommended Phase 2 dose (RP2D). Part 2 assessed the preliminary efficacy of tislelizumab in combination with fruquintinib in participants as measured by the overall response rate (ORR) and other efficacy and safety profiles.
This was an open label, multicenter, Phase 2 study designed to assess the efficacy and safety of tislelizumab in combination with fruquintinib in patients with advanced or metastatic, unresectable GC, and CRC or NSCLC. The study was conducted in 2 parts.
Part 1 of the study was the safety run-in stage which assessed dose-limiting toxicities (DLTs) and RP2D. Part 2 began at RP2D. Participants enrolled in Part 1 at RP2D were counted towards Part 2; up to approximately 30 patients per cohort were enrolled at RP2D.
The primary outcome measure of the study was ORR as assessed by the investigator as per response evaluation criteria in solid tumors (RECIST) version (v) 1.1. Tislelizumab and fruquintinib were administered until disease progression, intolerable toxicity, death, withdrawal of consent or until the study terminates.
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with advanced or metastatic, unresectable GC received fruquintinib 5 milligrams (mg) daily (3 weeks receiving fruquintinib followed by 1 week off) in combination with tislelizumab 300 mg intravenously on Day 1 of every 4-week cycle (each cycle of 28-days) until disease progression, unacceptable toxicity, or withdrawal for other reasons, whichever occurred first.
Drug: Tislelizumab · Drug: Fruquintinib
Participants with advanced or metastatic, unresectable CRC received fruquintinib 5 mg daily (3 weeks receiving fruquintinib followed by 1 week off) in combination with tislelizumab 300 mg intravenously on Day 1 of every 4-week cycle (each cycle of 28-days) until disease progression, unacceptable toxicity, or withdrawal for other reasons, whichever occurred first.
Drug: Tislelizumab · Drug: Fruquintinib
Participants with programmed cell death protein ligand-1 (PD-L1) expression, and advanced or metastatic, unresectable non-small cell lung cancer (NSCLC) received fruquintinib 5 mg daily (3 weeks receiving fruquintinib followed by 1 week off) in combination with tislelizumab 300 mg intravenously on Day 1 of every 4-week cycle (each cycle of 28-days) until disease progression, unacceptable toxicity, or withdrawal for other reasons, whichever occurred first.
Drug: Tislelizumab · Drug: Fruquintinib
Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD 1.
Also known as: BGB-A317
Fruquintinib is a potent, oral VEGFR tyrosine kinase inhibitor (TKI)
Also known as: HMPL-013
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
A DLT was defined as 1 of the following toxicities (Grade 3 or 4 Hematologic or Nonhematologic toxicities) occurring during the DLT assessment window and considered by the investigator to be related to 1 or more study drugs. All toxicities or adverse events (AEs) were graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0).
Time frame: Up to 28 Days
Part 1: Recommended Phase 2 Dose (RP2D)
RP2D for Part 2 was determined by evaluating safety and DLTs in Part 1 participants.
Time frame: Up to 28 Days
Objective Response Rate (ORR) as Assessed by the Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1
ORR was defined as the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR). Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From date of randomization until the date of first documented progression or death from any cause, whichever came first (up to 2 years and 9 months)
Progression-Free Survival (PFS) as Assessed by Investigator Based on RECIST v1.1
PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of progressive disease (PD) or death, whichever occurs first. Median PFS was estimated using the Kaplan-Meier method. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.
Time frame: From date of first dose of study drug until the date of first documented progression or death from any cause, whichever came first (up to 2 years and 9 months)
Disease Control Rate (DCR) as Assessed by the Investigator Based on RECIST v1.1
DCR was defined as the percentage of participants whose best overall response is CR, PR, or stable disease (SD) as assessed by investigator as per RECIST v1.1. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: From date of randomization until the date of first documented progression or death from any cause, whichever came first (up to 2 years and 9 months)
Clinical Benefit Rate (CBR) as Assessed by the Investigator Based on RECIST v1.1
CBR was defined as the percentage of participants whose best overall response is CR, PR, or durable stable disease (SD) as assessed by the investigator per RECIST v1.1. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: From date of randomization until the date of first documented progression or death from any cause, whichever came first (up to 2 years and 9 months)
Duration of Response (DOR) as Assessed by The Investigator Based on RECIST v1.1
DOR was defined as the time from the first occurrence of documented objective response to the time of progression as assessed by investigator per RECIST v1.1 or death from any cause, whichever occurs first. Median DOR was estimated using the Kaplan-Meier method.
Time frame: From the first objective response to the date of first documentation of disease progression or death, whichever occurs first (up to 2 years and 9 months)
Overall Survival (OS)
OS was defined as the time from the date of first dose to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.
Time frame: From the first dose of the study treatment to date of death from any cause (up to 2 years and 9 months)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs, Grade 3 or Higher TEAEs, TEAEs Leading to Death, TEAEs Related to Tislelizumab, TEAEs Related to Fruquintinib
A TEAE was defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug(s) and up to 30 days following study drug(s) discontinuation or initiation of new anticancer therapy, whichever occurred first determined according to NCI-CTCAE v5.0. Treatment emergent serious Adverse Events (TESAEs): any untoward medical occurrence at any dose: resulted in death; was life threatening; required prolong inpatient hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect or was considered a significant medical event by the investigator. AEs were graded for severity using NCI-CTCAE v5.0, where Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4 - Life-threatening consequences; and Grade 5: Death related to AE. The TEAEs leading to death in this data table exclude death due to disease under study.
Time frame: From the date of the first dose of study drug up to 30 days after the last dose of study drug; up to approximately 2 years and 5 months.
| Milestone | Gastric Cancer (GC): Tislelizumab and Fruquintinib | Colorectal Cancer (CRC): Tislelizumab and Fruquintinib | PD-L1 + NSCLC: Tislelizumab and Fruquintinib |
|---|---|---|---|
| Started | 31 | 31 | 22 |
| Completed | 2 | 3 | 7 |
| Not completed | 29 | 28 | 15 |
| Withdrew: Death | 24 | 24 | 8 |
| Withdrew: Closed by sponsor | 4 | 4 | 5 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
A DLT was defined as 1 of the following toxicities (Grade 3 or 4 Hematologic or Nonhematologic toxicities) occurring during the DLT assessment window and considered by the investigator to be related to 1 or more study drugs. All toxicities or adverse events (AEs) were graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0).
| Participants | Tislelizumab and Fruquintinib |
|---|---|
| Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) | 0 |
RP2D for Part 2 was determined by evaluating safety and DLTs in Part 1 participants.
| milligrams (mg) per day | Tislelizumab and Fruquintinib |
|---|---|
| Part 1: Recommended Phase 2 Dose (RP2D) | 5.0 |
ORR was defined as the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR). Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Gastric Cancer (GC): Tislelizumab and Fruquintinib | Colorectal Cancer (CRC): Tislelizumab and Fruquintinib | PD-L1 + NSCLC: Tislelizumab and Fruquintinib |
|---|---|---|---|
| Objective Response Rate (ORR) as Assessed by the Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 | 12.9 (3.6 to 29.8) | 9.7 (2.0 to 25.8) | 40.9 (20.7 to 63.6) |
PFS was defined as the time from the date of the first dose of study drug(s) to the date of the confirmed documentation of progressive disease (PD) or death, whichever occurs first. Median PFS was estimated using the Kaplan-Meier method. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.
| months | Gastric Cancer (GC): Tislelizumab and Fruquintinib | Colorectal Cancer (CRC): Tislelizumab and Fruquintinib | PD-L1 + NSCLC: Tislelizumab and Fruquintinib |
|---|---|---|---|
| Progression-Free Survival (PFS) as Assessed by Investigator Based on RECIST v1.1 | 4.6 (3.4 to 7.4) | 4.6 (3.6 to 7.2) | 15.6 (1.8 to NA) |
DCR was defined as the percentage of participants whose best overall response is CR, PR, or stable disease (SD) as assessed by investigator as per RECIST v1.1. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| percentage of participants | Gastric Cancer (GC): Tislelizumab and Fruquintinib | Colorectal Cancer (CRC): Tislelizumab and Fruquintinib | PD-L1 + NSCLC: Tislelizumab and Fruquintinib |
|---|---|---|---|
| Disease Control Rate (DCR) as Assessed by the Investigator Based on RECIST v1.1 | 74.2 (55.4 to 88.1) | 74.2 (55.4 to 88.1) | 68.2 (45.1 to 86.1) |
CBR was defined as the percentage of participants whose best overall response is CR, PR, or durable stable disease (SD) as assessed by the investigator per RECIST v1.1. Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| percentage of participants | Gastric Cancer (GC): Tislelizumab and Fruquintinib | Colorectal Cancer (CRC): Tislelizumab and Fruquintinib | PD-L1 + NSCLC: Tislelizumab and Fruquintinib |
|---|---|---|---|
| Clinical Benefit Rate (CBR) as Assessed by the Investigator Based on RECIST v1.1 | 32.3 (16.7 to 51.4) | 38.7 (21.8 to 57.8) | 59.1 (36.4 to 79.3) |
DOR was defined as the time from the first occurrence of documented objective response to the time of progression as assessed by investigator per RECIST v1.1 or death from any cause, whichever occurs first. Median DOR was estimated using the Kaplan-Meier method.
| months | Gastric Cancer (GC): Tislelizumab and Fruquintinib | Colorectal Cancer (CRC): Tislelizumab and Fruquintinib | PD-L1 + NSCLC: Tislelizumab and Fruquintinib |
|---|---|---|---|
| Duration of Response (DOR) as Assessed by The Investigator Based on RECIST v1.1 | NA (5.6 to NA) | 11.9 (3.7 to NA) | NA (7.7 to NA) |
OS was defined as the time from the date of first dose to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.
| months | Gastric Cancer (GC): Tislelizumab and Fruquintinib | Colorectal Cancer (CRC): Tislelizumab and Fruquintinib | PD-L1 + NSCLC: Tislelizumab and Fruquintinib |
|---|---|---|---|
| Overall Survival (OS) | 10.5 (5.2 to 14.6) | 10.0 (4.7 to 15.2) | NA (6.0 to NA) |
A TEAE was defined as an AE that had an onset date or a worsening in severity from baseline (pre-treatment) on or after the first dose of study drug(s) and up to 30 days following study drug(s) discontinuation or initiation of new anticancer therapy, whichever occurred first determined according to NCI-CTCAE v5.0. Treatment emergent serious Adverse Events (TESAEs): any untoward medical occurrence at any dose: resulted in death; was life threatening; required prolong inpatient hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect or was considered a significant medical event by the investigator. AEs were graded for severity using NCI-CTCAE v5.0, where Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4 - Life-threatening consequences; and Grade 5: Death related to AE. The TEAEs leading to death in this data table exclude death due to disease under study.
| Participants | Gastric Cancer (GC): Tislelizumab and Fruquintinib | Colorectal Cancer (CRC): Tislelizumab and Fruquintinib | PD-L1 + NSCLC: Tislelizumab and Fruquintinib |
|---|---|---|---|
| TEAEs | 30 | 31 | 22 |
| TESAEs | 13 | 14 | 13 |
| Grade 3 or Higher TEAEs | 18 | 21 | 18 |
| TEAEs Leading to Death | 3 | 0 | 1 |
| TEAEs Related to Tislelizumab | 20 | 22 | 16 |
| TEAEs Related to Fruquintinib | 25 | 26 | 19 |
Collected over All-cause mortality data was collected through the end of study, that is, up to 2 years 9 months. Adverse event data was collected from the date of the first dose of study drug up to 30 days after the last dose of study drug (up to approximately 2 years and 5 months).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gastric Cancer (GC): Tislelizumab and Fruquintinib | 24/31 (77.4%) | 13/31 (41.9%) | 28/31 (90.3%) |
| Colorectal Cancer (CRC): Tislelizumab and Fruquintinib | 24/31 (77.4%) | 14/31 (45.2%) | 29/31 (93.5%) |
| PD-L1 + NSCLC: Tislelizumab and Fruquintinib | 8/22 (36.4%) | 13/22 (59.1%) | 19/22 (86.4%) |
| Event | Gastric Cancer (GC): Tislelizumab and Fruquintinib | Colorectal Cancer (CRC): Tislelizumab and Fruquintinib | PD-L1 + NSCLC: Tislelizumab and Fruquintinib |
|---|---|---|---|
| DeathGeneral disorders | 3/31 | 0/31 | 2/22 |
| General physical health deteriorationGeneral disorders | 2/31 | 3/31 | 0/22 |
| HypopituitarismEndocrine disorders | 0/31 | 0/31 | 2/22 |
| Hepatic function abnormalHepatobiliary disorders | 2/31 | 0/31 | 0/22 |
| COVID-19Infections and infestations | 0/31 | 2/31 | 0/22 |
| Cardiac failure acuteCardiac disorders | 0/31 | 0/31 | 1/22 |
| Immune-mediated myocarditisCardiac disorders | 0/31 | 0/31 | 1/22 |
| Ventricular arrhythmiaCardiac disorders | 0/31 | 0/31 | 1/22 |
| Retinal artery occlusionEye disorders | 0/31 | 0/31 | 1/22 |
| Intestinal obstructionGastrointestinal disorders | 0/31 | 0/31 | 1/22 |
| Event | Gastric Cancer (GC): Tislelizumab and Fruquintinib | Colorectal Cancer (CRC): Tislelizumab and Fruquintinib | PD-L1 + NSCLC: Tislelizumab and Fruquintinib |
|---|---|---|---|
| ProteinuriaRenal and urinary disorders | 7/31 | 13/31 | 7/22 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 10/31 | 4/31 | 9/22 |
| Weight decreasedInvestigations | 11/31 | 3/31 | 3/22 |
| AnaemiaBlood and lymphatic system disorders | 10/31 | 6/31 | 4/22 |
| HypothyroidismEndocrine disorders | 7/31 | 10/31 | 4/22 |
| DiarrhoeaGastrointestinal disorders | 2/31 | 10/31 | 4/22 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/31 | 0/31 | 6/22 |
| HypertensionVascular disorders | 7/31 | 6/31 | 5/22 |
| Aspartate aminotransferase increasedInvestigations | 4/31 | 7/31 | 3/22 |
| White blood cell count decreasedInvestigations | 7/31 | 1/31 | 2/22 |
Analysis was performed on safety analysis set that included all participants who received at least 1 dose of study drug(s).
| Age, Continuous(years) | Gastric Cancer (GC): Tislelizumab and Fruquintinib | Colorectal Cancer (CRC): Tislelizumab and Fruquintinib | PD-L1 + NSCLC: Tislelizumab and Fruquintinib | Total |
|---|---|---|---|---|
| Mean | 59.0 ± 8.71 | 58.8 ± 7.88 | 63.5 ± 11.28 | 60.1 ± 9.29 |
| Sex: Female, Male(Participants) | Gastric Cancer (GC): Tislelizumab and Fruquintinib | Colorectal Cancer (CRC): Tislelizumab and Fruquintinib | PD-L1 + NSCLC: Tislelizumab and Fruquintinib | Total |
|---|---|---|---|---|
| Female | 10 | 11 | 5 | 26 |
| Male | 21 | 20 | 17 | 58 |
| Race (NIH/OMB)(Participants) | Gastric Cancer (GC): Tislelizumab and Fruquintinib | Colorectal Cancer (CRC): Tislelizumab and Fruquintinib | PD-L1 + NSCLC: Tislelizumab and Fruquintinib | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 30 | 31 | 22 | 83 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beigene.com
Ran from Apr 2021 to primary completion in Feb 2024, 34 months.
Results were first posted in Mar 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tislelizumab · HMPL-013